Opinion|Videos|December 11, 2024
Drug Classes Available to Treat Patients With High Blood Pressure
Key Takeaways
- Antihypertensive drug classes include diuretics, beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, and alpha-blockers, each with distinct mechanisms of action targeting blood pressure regulation.
- Diuretics reduce blood volume, beta-blockers decrease heart rate, ACE inhibitors and ARBs inhibit the renin-angiotensin-aldosterone system, and calcium channel blockers relax blood vessels.
Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- There are numerous traditional drug classes available to treat patients with high blood pressure.
- What are the main antihypertensive drug classes and what are their mechanisms of action?
- What are some nonpharmacological approaches for treating hypertension?
Advertisement
Related to this article
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.
Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease
3
When Innovation Builds Clinical Confidence: Evaluating Treatment Options in Hemophilia A
4
The HCPFive: Top News for Healthcare Providers from the Week of 09/13
5